Specific strains of intestinal bacteria can improve the response rate to immunotherapy for patients being treated for advanced melanoma. Patients with a higher ratio of ‘beneficial’ bacteria to ‘non-beneficial’ bacteria all showed a clinical response: a reduction in tumor size.